NP5 Stock Overview
A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Newron Pharmaceuticals S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 8.03 |
| 52 Week High | CHF 11.90 |
| 52 Week Low | CHF 6.03 |
| Beta | 0.59 |
| 1 Month Change | 6.92% |
| 3 Month Change | -27.00% |
| 1 Year Change | -17.47% |
| 3 Year Change | 471.53% |
| 5 Year Change | 352.14% |
| Change since IPO | -34.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| NP5 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -5.6% | 2.0% | -0.9% |
| 1Y | -17.5% | -25.8% | 14.1% |
Return vs Industry: NP5 exceeded the German Pharmaceuticals industry which returned -25.8% over the past year.
Return vs Market: NP5 underperformed the German Market which returned 14.1% over the past year.
Price Volatility
| NP5 volatility | |
|---|---|
| NP5 Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: NP5 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: NP5's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 22 | Stefan Weber | www.newron.com |
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication.
Newron Pharmaceuticals S.p.A. Fundamentals Summary
| NP5 fundamental statistics | |
|---|---|
| Market cap | €157.99m |
| Earnings (TTM) | €15.84m |
| Revenue (TTM) | €51.39m |
Is NP5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NP5 income statement (TTM) | |
|---|---|
| Revenue | €51.39m |
| Cost of Revenue | €0 |
| Gross Profit | €51.39m |
| Other Expenses | €35.55m |
| Earnings | €15.84m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Sep 16, 2025
| Earnings per share (EPS) | 0.79 |
| Gross Margin | 100.00% |
| Net Profit Margin | 30.83% |
| Debt/Equity Ratio | 3,405.8% |
How did NP5 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/25 00:42 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Newron Pharmaceuticals S.p.A. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Meyer | Baader Helvea Equity Research |
| Bob Pooler | Bank am Bellevue |
| Maria Maldonado | Bank Vontobel AG |